Abstract
Objective To systematically evaluate the clinical effectiveness and safety of Breviscapine injection combined with conventional therapy in the treatment of unstable angina pectoris (UAP). Methods The literature were systematicly retrieved about the randomized controlled trials (RCTs) of Breviscapine injection for UAP. The Cochrane Risk of Bias Assessment Table was used to evaluate the methodological quality of the RCTs and then the data were extracted and meta-analysed by RevMan 5.3 software. Results A total of 15 RCTs with 1202 participants were included. In the meta-analysis, the combination of Breviscapine injection and conventional therapy in the treatment of UAP can achieve better angina pectoris curative effect (Z=7.74, P<0.01), the RR (95% CI) was 1.23 (1.17,1.30), and the electrocardiogram curative effect (Z=6.26, P<0.01), the RR (95% CI) was 1.32(1.21, 1.44). Furthermore, Breviscapine injection can improve hemorheologic parameters. And there was no major or serious adverse drug event. Conclusions The Breviscapine injection combined with conventional therapy shows good therapeutic effect on UAP. Key words: Angina, unstable; Randomized controlled trials; Meta-analysis; Breviscapine injection
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
